

Clinical Microbiology: Empowering Detection

CHROMagar™ has developed a range of selective culture media for the rapid detection of clinically relevant pathogens, enhancing diagnostic speed and accuracy for better patient outcomes.




CHROMagar™
Acinetobacter



CHROMagar™
Orientation



CHROMagar™
STEC



CHROMagar™
B.cepacia




CHROMagar™
Salmonella




CHROMagar™
Strep A




CHROMagar™
C.difficile




CHROMagar™
Serratia



CHROMagar™
Strep B



CHROMagar™
Campylobacter



CHROMagar™
Staph aureus



LIM RambaQUICK™
Strep B

**ASK YOUR LOCAL DISTRIBUTOR
FOR MORE INFORMATION**

Reference contact :

CHROMagar™
The Chromogenic Media Pioneer

CHROMagar.com

CHROMagar, 29 avenue George Sand, 93210 La Plaine Saint-Denis, France
For more informations about our products and technical documents, please refer to our website.

© 2024 CHROMagar
LF-EXT-095-EN

CHROMagar™ Candida Plus

For detection and differentiation of major clinical
Candida species, including *C. auris*



CHROMagar™
The Chromogenic Media Pioneer

Candida: A Growing Threat listed on the WHO Fungal Priority


Overview

Over the past decade, infections caused by *Candida* species have risen, largely due to an increasing number of vulnerable individuals.


The WHO recently highlighted *Candida albicans*, *Candida auris* and *Candida glabrata* as priority pathogens, with *C. albicans* leading global candidemia cases.

Additionally, *Candida auris*, an emerging multidrug-resistant pathogen associated to nosocomial infections, presents detection challenges.

Pathogenesis



CHROMagar™ *Candida* Plus is the first chromogenic isolation medium to detect and differentiate *C. auris* in addition to other major clinical *Candida* species such as *C. albicans*, *C. tropicalis*, *C. glabrata* or *C. krusei*.




Candida spp. : Data and Insights


72% of global *Candida* incidence is attributed to *C. albicans*, *C. glabrata* and *C. tropicalis*, according to multiple studies¹

C. albicans causes annually:

- + 150 million** mucosal infections²
- ~ 200,000** deaths²
- ~ \$2 billion** losses in healthcare in US²



Candida auris: The Emerging Superbug



Recent reports indicate a significant rise in *Candida auris* infections in one year :

96% increase in *Candida auris* cases has been reported in Europe.³

61% increase in *Candida auris* cases has been reported in United States of America⁴

Medium performance



EASY TO READ:

The medium is highly effective in differentiating various *Candida* species based on colony color and morphology.



DETECTION OF *CANDIDA AURIS*:

CHROMagar™ *Candida* Plus is particularly useful for identifying *Candida auris*, a multidrug-resistant species that poses significant challenges in healthcare settings



COST-EFFECTIVE

Using CHROMagar™ *Candida* Plus reduces the need for multiple tests or specialized media for differentiating *Candida* species, lowering the overall costs



HIGH SENSITIVITY AND SPECIFICITY:

The medium provides high sensitivity and specificity for differentiating clinically important *Candida* species, making it a reliable tool for diagnostic laboratories.



SAMPLES :

Swabs from skin, throat, ears, vagina as well as sputum,



RESULTS:

Can be interpreted within 24/48h of aerobic incubation at 30-37 °C

¹Riera et al. 2022. *Antibiotics* (Basel), Richardson et al. 2022. *Pathogens*, Fuller et al. 2019. *J Antimicrob Chemother*, Bilal et al. 2022. *Virulence*, Morii et al. 2014. *J Infect Chemother*, Mirhendi et al. 2020. *Medical Mycology*, Schmalreck et al. 2012. *Mycoses*

²Richardson et al. 2022. *Pathogens*

³Kohlenberg et al. 2022. *Eurosurveillance*

⁴CDC. *Candida auris*

⁵Mulet Bayona et al. 2020. *Diagn Microbiol Infect Dis*